Efficacy of Lenvatinib Therapy for Thyroid Cancer by Pathological Type: A Retrospective Real-world Study
Lenvatinib may be effective in patients with DTC in whom RAI treatment is not feasible in real-world settings.
Authors
- Kenji TSUCHIHASHI
- Takashi Nakagawa (ORCID: https://orcid.org/0000-0001-5539-7605)
- Ryunosuke Kogo (ORCID: https://orcid.org/0000-0002-7030-7302)
- Mioko Matsuo (ORCID: https://orcid.org/0000-0002-9158-1298)
- Mamoru Ito (ORCID: https://orcid.org/0000-0002-9300-825X)
- Hirofumi Ohmura (ORCID: https://orcid.org/0000-0003-4650-9120)
- Masanobu Sato (ORCID: https://orcid.org/0000-0001-7108-0376)
- Kazuki Hashimoto (ORCID: https://orcid.org/0000-0002-8324-2202)
- Shogo Masuda
Institutions
- Kyushu University (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2025-08-28
- DOI
- https://doi.org/10.21873/invivo.14085
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GlaxoSmithKline